NASDAQ: LUNGPulmonx Corp Stock
$3.35+0.01 (+0.3%)
Updated May 20, 2025
LUNG Price
$3.35
Fair Value Price
N/A
Market Cap
$134.86M
52 Week Low
$3.18
52 Week High
$9.37
P/E
-2.33x
P/B
1.74x
P/S
3.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$87.47M
Earnings
-$57.09M
Gross Margin
73.5%
Operating Margin
-60.86%
Profit Margin
-65.3%
Debt to Equity
0.94
Operating Cash Flow
-$33M
Beta
1.31
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LUNG Overview
Pulmonx Corporation is a medical technology company offering minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. Its Zephyr Endobronchial Valve is a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema. The Chartis Pulmonary Assessment System is a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. Pulmonx was incorporated in 1995 and is headquartered in Redwood City, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LUNG's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
D
LUNG
Ranked#58 of 111
Ranked#58 of 111
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $29.41 | A | |
| $22.22 | A | |
| $281.13 | A |
Be the first to know about important LUNG news, forecast changes, insider trades & much more!
LUNG News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LUNG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LUNG is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LUNG is good value based on its book value relative to its share price (1.74x), compared to the US Medical Devices industry average (4.1x)
P/B vs Industry Valuation
LUNG is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LUNG due diligence checks available for Premium users.
Valuation
LUNG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.33x
Industry
37.96x
Market
25.56x
LUNG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.74x
Industry
4.1x
LUNG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LUNG's financial health
Profit margin
Revenue
$22.5M
Net Income
-$14.4M
Profit Margin
-64.1%
LUNG's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LUNG's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$150.7M
Liabilities
$73.1M
Debt to equity
0.94
LUNG's short-term assets ($123.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LUNG's short-term assets ($123.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LUNG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.2M
Investing
$16.3M
Financing
$664.0k
LUNG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LUNG vs Medical Device Stocks
Pulmonx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.